Our founder Yutaka Mizushima (emeritus professor of St. Marianna Medical University, the first Parliamentary Secretary for Education, Culture, Sports, Science and Technology, Upper House member) is one of the pioneers in DDS research in Japan, and we are proud that we are a leading company in the DDS field.
Our DDS product, lipo-PGE1 achieved a sales peak of over 50 billion yen in Japan. Our affiliated company, Beijing Tide Pharmaceutical, achieved sales of close to 30 billion yen after successful launching lipo-PGE1 in China (within the top 10 selling pharmaceuticals).
Lipo-PGE1 prevents deactivation of PGE1 and allows targeting of PGE1 in an affected site by encapsulation of lipid emulsion, which was first used for a DDS product. Based on this technology, we successfully developed lipid emulsion pharmaceuticals, such as lipo-NSAID. This lipo-NSAID has also become a major product of Beijing Tide Pharmaceutical with sales of over 20 billion yen.
Subsequently, we have continued to develop the new, world-first DDS technologies and strived to commercialize them as pharmaceuticals. For example, PC-SOD, into which we put the most effort, is a DDS product with pharmaceutical activity significantly increased by binding phospholipids to a protein called SOD (lecithinization). We are the only company that possesses the technology for lecithinizing protein, which can be applied to other kinds of proteins. Thus, taking advantage of this our original lecithinization technology, we propose the joint development of improved biologics. Specifically, after receiving a request from the partner company, we would develop a lecithinized formulation of a distinct biologics.
Moreover, we developed an epoch-making DDS technology called stealth-type nanoparticles. Unlike conventional DDS carriers focusing on either of targeting (selective drug delivery to an affected site) or controlled-release (slowing of drug release), our stealth-type polymeric nanoparticles are the world-first DDS carrier successfully achieving on both of these functions. For example, PGE1-encapsulated nanoparticles (nano-PGE1) have more of a pharmacological effect with less dosage and dose frequency than lipo-PGE1 because this accumulates and releases PGE1 on an affected vascular site. In addition, active targeting is also possible by coating the surface of nanoparticles with ligand molecule for a particular tissue or cell. For example, we encapsulated an antiviral drug into nanoparticles, whose surface is coated with galactose to improve their accumulation to the liver and to achieve sustained release of the drug. For stealth-type polymeric nanoparticles, see references as below. Since this is the first DDS carrier that achieves both sustained-release and targeting, encapsulation of various drugs in the stealth nanoparticles is expected to improve their efficacy and safety, we propose the joint drug development using this DDS carrier. We could encapsulate the drug in the stealth nanoparticles in response to proposal d from the partner company.
In addition to facts that we have a variety of DDS technology, we have the know-how to develop new DDS technology. So, not only the joint research using our DDS technology proposed above, we would like to propose joint research to develop a new DDS technology and an improved drug, in response to request from the partner company (sustained release, targeting, etc.). For example, stabilization of protein formulations, stabilization and organ selective delivery of small molecule drugs by a variety of drug carrier, such as lipid emulsion, solid particles, polymer micelles, and liposomes, intracellular delivery of nucleic acid drugs for gene therapy (such as siRNA), the development of subcutaneous injection of drug- encapsulated microparticles (sustained-release formulation) are considered to be possible by using our know-how and core technologies (such as drug encapsulation technology) for DDS formulation.